Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01), Zacks reports. The business had revenue of $7.97 million during the quarter, compared to analysts' expectations of $8.30 million. Eton Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 6.21%. During the same period last year, the company posted ($0.10) EPS.
Eton Pharmaceuticals Price Performance
Shares of NASDAQ:ETON remained flat at $3.43 during trading on Friday. The stock had a trading volume of 139,532 shares, compared to its average volume of 66,947. The company has a market cap of $88.11 million, a P/E ratio of -114.50 and a beta of 1.19. The company has a 50 day moving average of $3.72 and a two-hundred day moving average of $4.06. Eton Pharmaceuticals has a 12-month low of $2.42 and a 12-month high of $5.81.
Analysts Set New Price Targets
Separately, Craig Hallum assumed coverage on Eton Pharmaceuticals in a research note on Monday. They set a "buy" rating and a $8.00 price objective on the stock.
Get Our Latest Research Report on ETON
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
